


# Total Synthesis of (–)-(α)-Kainic Acid via a Diastereoselective Methylenecyclopropane Ring Expansion

Mark E. Scott and Mark Lautens\*

Davenport Research Laboratories, Department of Chemistry, University of Toronto,  
80 St. George Street, Toronto, Ontario, M5S 3H6, Canada  
mlautens@chem.utoronto.ca


Received May 3, 2005

## ABSTRACT



A concise and enantioselective synthesis of (–)-(α)-kainic acid in 13 steps with an overall yield of 15% is reported. The pyrrolidine kainoid precursor with the required C2/C3 trans stereochemistry was prepared with excellent diastereoselectivity (>20:1) via a  $MgI_2$ -mediated ring expansion of a tertiary methylenecyclopropyl amide. A selective hydroboration was then employed to set the remaining stereochemistry at the C4 position en route to (–)-(α)-kainic acid.


The kainoid amino acids are a potent class of neuroexcitant compounds whose biological activity stems from their ability to function as a conformationally restricted analogue of glutamic acid. For this reason, these amino acids have been used extensively by the neurological community in the study of Huntington's chorea and Alzheimer's disease.<sup>1</sup> Typically, these amino acids are composed of a *trans*-C2,C3/*cis*-C3,C4 pyrrolidine core which differs solely in the nature of the substituent at the 4-position.



Recently, we reported a highly diastereoselective route to *trans*-C2,C3-pyrrolidines using a magnesium iodide-mediated ring expansion of methylenecyclopropanes in the presence of a chiral sulfinimine.<sup>2</sup> Enantiopure pyrrolidines could then be obtained upon deprotection of the chiral auxiliary. We now report the use of this methodology toward the total synthesis of the (–)-(α)-kainic acid<sup>3</sup> **1** using the retro-

synthetic methodology outlined in Scheme 1. Scheme 2 shows the synthesis of (–)-kainic acid.

## Scheme 1. Retrosynthetic Analysis



$MgI_2$ -mediated ring expansion of *N,N*-diphenylmethylenecyclopropyl amide **2** in the presence of chiral sulfinimine **3** gave the expected pyrrolidine **4** ( $[\alpha]_D -55.2^\circ$  (*c* 1.11,

2 + 3  $\xrightarrow[\text{THF}]{1 \text{ equiv MgI}_2}$  4 (78%)

4  $\xrightarrow[\text{NaOH/H}_2\text{O}_2]{9\text{-BBN, THF, } 50^\circ\text{C}}$  5 (91%)

5  $\xrightarrow[0^\circ\text{C}]{\text{TEMPO/NaOCl}}$  6 (91% dr = 98:2)

6  $\xrightarrow[\text{THF, } 0^\circ\text{C}]{5 \text{ mol\% KO}^t\text{Bu}}$  7 (99% dr = 60:40)

7  $\xrightarrow[\text{THF, } -78^\circ\text{C}]{\text{MeMgBr}}$  8 (86% dr = 60:40)

8  $\xrightarrow[\text{THF, } 0^\circ\text{C}]{3.5 \text{ equiv Ph}_3\text{PCH(OMe)}}$  9 (95% over 2 steps, E:Z = 5.4:1, dr = 60:40)

9  $\xrightarrow[\text{THF/H}_2\text{O, then KI}]{\text{Hg(OAc)}_2, \text{THF/H}_2\text{O}}$  10 (91%)

10  $\xrightarrow[\text{THF, } -78^\circ\text{C}]{3\text{N LiOH, MeOH}}$  11 (87%, E:Z = 5.4:1)

11  $\xrightarrow[\text{then CH}_2\text{N}_2]{\text{RuCl}_3/\text{NaIO}_4, 30^\circ\text{C}}$  12 (75%)

12  $\xrightarrow[\text{then recrystallization}]{\text{Amberlite CG50}}$  13 (X = O) (70%)

13  $\xrightarrow[\text{then recrystallization}]{\text{Li/NH}_3, \text{THF, } -78^\circ\text{C}}$  14 (X = CH<sub>2</sub>) (71%)

14  $\xrightarrow[\text{then recrystallization}]{\text{Zn/TiCl}_4/\text{CH}_2\text{I}_2}$  1 (70%)

(1) (a) *Kainic Acid as a Tool in Neurobiology*; McGeer, E. G., Olney, J. W., McGeer, P. L., Eds.; Raven: New York, 1978. (b) *Excitatory Amino Acids*; Simon, R. P., Ed.; Thieme Medical: New York, 1992. (c) Moloney, M. G. *Nat. Prod. Rep.* **1990**, *16*, 485. (d) Moloney, M. G. *Nat. Prod. Rep.* **1998**, *15*, 205.

(3) For a review of previous syntheses of kainic acid, see: (a) Parsons, A. F. *Tetrahedron* **1996**, *52*, 4149. For some recent syntheses of kainic acid, see: (b) Hodgson, D. M.; Hachisu, S.; Andrews, M. D. *Org. Lett.* **2005**, *7*, 815. (c) Martinez, M. M.; Hoppe, D. *Org. Lett.* **2004**, *6*, 3743. (d) Anderson, J. C.; Whiting, M. J. *Org. Chem.* **2003**, *68*, 6160. (e) Trost, B. M.; Rudd, M. T. *Org. Lett.* **2003**, *5*, 1467. (f) Clayden, J.; Menet, C. J.; Mansfield, D. J. *Chem. Commun.* **2002**, *1*, 38. (g) Clayden, J.; Menet, C. J.; Tchabanenko, K. *Tetrahedron* **2002**, *58*, 4727. (h) Hirasawa, H.; Taniguchi, T.; Ogasawara, K. *Tetrahedron Lett.* **2001**, *42*, 7587. (i) Xia, Q.; Ganem, B. *Org. Lett.* **2001**, *3*, 485. (j) Campbell, A. D.; Raynham, T. M.; Taylor, R. J. K. *J. Chem. Soc., Perkin Trans. 1* **2000**, *19*, 3194. (k) Nakagawa, H.; Sugahara, T.; Ogasawara, K. *Org. Lett.* **2000**, *2*, 3181. (l) Miyata, O.; Ozawa, Y.; Ninomiya, I.; Naito, T. *Tetrahedron* **2000**, *56*, 6199. (m) Clayden, J.; Tchabanenko, K. *Chem. Commun.* **2000**, *4*, 317. (n) Cossy, J.; Cases, M.; Pardo, D. G. *Synlett* **1998**, 507. (o) Bachi, M. D.; Melman, A. J. *Org. Chem.* **1997**, *62*, 1896.

Conversion of **14** to **1** was then carried out as previously reported by Yoo and co-workers.<sup>6a,9</sup> Ester hydrolysis followed by tosyl deprotection using Birch conditions afforded crude **1** from **14**. Purification of **1** was then carried out using an ion-exchange resin (Amberlite CG50) followed by recrystallization to afford optically pure (–)-(α)-kainic acid ([α]<sub>D</sub><sup>20</sup>

(9) Yoo, S.; Lee, S. H. *J. Org. Chem.* **1994**, *59*, 6968.

$-14.3^{\circ}$  ( $c$  0.8,  $H_2O$ ), natural  $(-)-(\alpha)$ -kainic acid  $[\alpha]^{23}_D$   $-14.6^{\circ}$  ( $c$  0.9,  $H_2O$ ))<sup>10</sup> in 70% yield over two steps.

In conclusion, we have successfully synthesized  $(-)-(\alpha)$ -kainic acid in enantiopure form in 13 linear steps. Initial ring expansion of the methylenecyclopropyl amide in the presence of a chiral sulfinimine set the first two stereocenters in one convenient step. A highly selective hydroboration using the bulky tertiary amide to control facial selectivity then set the remaining stereocenter en route to the final product.

---

(10) An authentic sample of natural  $(-)-(\alpha)$ -kainic acid was obtained from Ocean Produce International, NS, Canada.

**Acknowledgment.** We thank Merck-Frosst Canada, the National Sciences and Engineering Research Council (NSERC) of Canada, and the University of Toronto for funding. We also thank Dr. Wooseok Han for helpful discussions. M.S. thanks NSERC (PGS-B) as well as the Sumner Foundation for scholarship funding.

**Supporting Information Available:** Experimental procedures for the preparation of new compounds and characterization data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL051003P